Combination Therapies: What Would Prove It, and What We Actually Have

*Combining treatments is normal and often correct in medicine. Proving that a particular combination beats its parts requires a particular kind of trial — and for the protocol described here, that trial has not been done.*

What Would Prove This, and Why It Matters

The case for combining is easy to state and easy to overstate. Ageing and chronic disease genuinely do involve many processes at once — the widely cited "hallmarks of ageing" describe several running in parallel¹⁷ — and it is reasonable to think one intervention may not address all of them.

But most of the confusion about combination therapy comes from a single missing distinction: a rationale is not a result.

The three things that get confused

The design that settles it

To show a combination beats its parts you need an arm that isolates the addition:

• Add-on design: everyone gets A; half also get B, half get placebo. One variable changes
• Factorial design: A alone vs B alone vs A+B vs neither
• Combination index: dose-response curves for each agent alone and combined, yielding CI < 1 (synergy), CI = 1 (additive) or CI > 1 (antagonism)¹

⚠️ The combination index framework exists precisely because intuition fails here. Two treatments that each work can interfere with each other. Chou's method — the standard reference for quantifying drug interaction — treats antagonism as an equally likely finding as synergy, and it cannot be evaluated without single-agent arms.

It is not possible to look at a combination's results and know whether the combination added anything. That is why the design matters.

What this looks like when it is done properly

Two dermatology trials illustrate the design, and we are including them because they are the standard this page's own claims should be held to:

Kwon et al. (2020)² — 12-week, prospective, double-blind, randomised, split-face trial, n = 25. Every patient received fractional CO₂ laser to the whole face. One side then received adipose-derived stem cell exosome gel; the other side received control gel. One variable changed. Result: acne-scar score reduction 32.5% vs 19.9% (p < 0.01), with milder erythema and shorter downtime on the exosome side.

Park et al. (2023)³ — 12-week, prospective, randomised split-face, n = 28. Microneedling on both sides; exosome-containing solution on one, saline on the other. Global Aesthetic Improvement Scale significantly higher on the treated side (p = 0.005).

⭐ These are real combination trials with real add-on designs. Note what they are: cell-free exosome products added to a procedure, in skin. Neither involves mesenchymal stem cells. Neither tests a sequencing protocol. They demonstrate that the objection to the claims below is not "such trials are impossible" — it is "they have not been done for this."

The Combinations We Offer, and the Evidence for Each

Stated plainly, one row at a time.

Five combinations, zero comparative trials. The one with the least supporting evidence — NAD+ before MSCs — is the one placed first in the protocol.

What Each Component Is, and What Is Established About It

NAD+

A coenzyme essential to energy metabolism and to sirtuin, PARP and CD38 function, which declines with age⁷. Established: oral precursors raise NAD+ metabolites in humans. Not established: that raising it produces functional benefit, and there are no outcomes trials of intravenous NAD+ for wellness indications⁵.

Exosomes and the MSC secretome

Nano-scale vesicles carrying proteins, lipids and RNA between cells, defined by international consensus criteria⁸.

⚠️ An honest note about the literature we cite here. The major review of MSC secretome⁹ argues that secretome shows "therapeutic effects similar to those observed after transplantation of MSCs" and "may bypass many side effects of MSC-based therapy" — proposing it as a cell-free alternative to cells. It does not compare cells-plus-secretome against either alone. If anything, it is an argument for choosing one rather than buying both.

Mesenchymal stromal cells

Defined by the International Society for Cellular Therapy minimal criteria¹⁰. They act largely through immunomodulation and paracrine signalling rather than engraftment^11,12 — a distinction that matters, because "the cells take up residence and rebuild tissue" and "the cells signal and are cleared" are different claims with different implications for how long any benefit should last.

⚠️ On the strength of the MSC evidence itself, since it is the component everything else is arranged around: a systematic review of stem cell injections in knee osteoarthritis found all six included trials at high risk of bias, yielding level-3 evidence, and concluded that in the absence of high-level evidence its authors do not recommend the treatment for that indication¹⁶. That is one indication and not the whole field, but it is the quality of evidence the base of this protocol rests on.

NK and NKT cells

Lymphocytes providing immune surveillance¹³.

⚠️ We are not going to claim these belong in a sequence with MSCs. MSCs suppress immune activity; NK/NKT therapy activates it. Whether administering one after the other helps, does nothing, or works against itself has not been studied in patients.

⚠️ The Safety Side of Combining

Combining treatments combines their risks, and the regenerative literature contains a specific warning worth reading before you consent to an infusion.

Moll et al. (2019)⁴ examined intravascular MSC products and found:

• "Different MSC products display varying levels of highly procoagulant tissue factor (TF) and may adversely trigger the instant blood-mediated inflammatory reaction (IBMIR)"
• Meta-analysis has shown bone-marrow MSC infusion is safe, but "it is not clear if this also applies to diverse new cell products derived from other sources, such as adipose and perinatal tissues"

⚠️ Umbilical cord MSCs are a perinatal product. That is what we use. The authors' point is that haemocompatibility should be assessed and controlled for each product type rather than assumed from bone-marrow data.

On safety generally: a systematic review of 36 clinical trials and 1,012 participants found intravascular MSC therapy broadly safe, with a significant association with transient fever and a call for "further larger scale controlled clinical trials with rigorous reporting of adverse events"¹⁴.

⚠️ And the specific point about combining: adding treatments adds their risks. No trial has characterised the adverse-event profile of the combined protocol, because no trial of the combined protocol exists.

Our Protocol, and the Reasoning Behind It

We do sequence these treatments, and you are entitled to know that the reasoning is mechanistic.

The argument: MSCs act largely by signalling to your tissues. Responding to those signals requires cellular energy and functional mitochondria. NAD+ is central to both. Exosomes may reduce local inflammation. So a recipient whose cells are energised and whose tissue is less inflamed might respond better.

Why that is not evidence: every step is plausible and none has been tested in the relevant comparison. Plausible mechanisms fail in trials routinely — that is what trials are for.

The schedule

⚠️ You can decline any component. MSC therapy without the Day 1 preparation is a reasonable choice, and we will not tell you it undermines the treatment — we do not know that it does.

What we will not tell you

• That the combination produces an 80% improvement, or any other number. No such figure exists for this protocol
• That preparation is necessary
• That more components produce proportionally better results
• That higher cell doses are better. ⚠️ In the randomised frailty trial often cited here, physical performance improved in the 100-million-cell group and not in the 200-million-cell group¹⁵. One trial, and it should not be over-read — but it points the opposite way to "more is better"

What Could Change Our Mind

We would consider the combination established if any of the following were published:

1. An add-on randomised trial: MSC therapy plus NAD+ preparation vs MSC therapy plus placebo infusion, with a clinical primary endpoint
2. A factorial trial separating NAD+, exosomes and MSCs
3. A combination index analysis¹ showing CI < 1 for any pairing offered here
4. Any registered trial of the sequencing protocol reporting results

None of these exists today. If one appears and is positive, this page will say so. If one appears and is negative, this page will say that too.

Where Combination Therapy Genuinely Is Established

⚖️ Reported at full strength, because dismissing the concept would be as wrong as overselling it.

Combination treatment is standard and often superior in:

• Oncology — multi-agent chemotherapy, and chemotherapy with immunotherapy, established by factorial and add-on trials
• HIV — combination antiretroviral therapy, one of the clearest demonstrations in medicine that combinations can outperform single agents
• Chronic disease — multiple antihypertensives at lower doses, or a drug plus structured exercise
• Musculoskeletal care — surgery plus rehabilitation, where the rehabilitation component has its own trial evidence

What these share is that somebody ran the trial. The principle is real. Its application to regenerative medicine is the part that has not yet been tested.

Frequently Asked Questions

Do I need all the components?

No. Many patients have MSC therapy alone. The additional components are offered because there is a mechanistic argument for them, not because withholding them is known to reduce benefit.

Is the combination better than MSCs alone?

Unknown. No trial has made that comparison. Anyone who tells you a figure for it is quoting something other than published data.

Why sequence them in this order?

The reasoning is that energy and inflammation status might affect how tissues respond to MSC signalling. It is a hypothesis. Reordering or removing components has not been tested either.

Isn't combining treatments obviously better?

Not obviously, and sometimes not at all. Combination index analysis exists because combinations can be antagonistic as well as synergistic¹ — and MSC therapy suppresses immune activity while NK/NKT therapy stimulates it, which is a reason for caution rather than confidence.

Is this supported by mainstream medicine?

The principle is thoroughly mainstream — oncology and HIV are built on it. The specific combinations here are not established, and we would be misrepresenting the situation if we let the first fact stand in for the second.

What if I can only afford part of the protocol?

MSC therapy is the component with the most evidence behind it and is the reasonable priority. We will design something within your budget and tell you honestly what each addition is and is not known to do.

Is combining these treatments safe?

Each has its own profile, and MSC infusion carries a documented association with transient fever¹⁴ and product-dependent haemocompatibility considerations⁴. The combined protocol's adverse-event profile has not been formally characterised, because it has not been trialled.

Take the Next Step

The honest summary: combination therapy is a legitimate idea, this particular combination is untested, and the reasoning behind it is mechanistic rather than evidential.

If that is a basis on which you are willing to proceed, we are glad to discuss it. If it is not, that is a reasonable conclusion and we would rather you reached it here than afterwards.

→ Take the 2-Minute Assessment

→ Schedule a Discovery Call — bring this page's questions with you